


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound having the following formula I:




wherein:

'X' represents an α -amino acid group wherein the α -amino group of the amino acid is bound to the R₁-O-CO- group and the carboxy group of the amino acid is bound to the R₂-CH₂-CO-(CH₂)_n-CH(CO₂H)-NH- group;

'n' is an integer between 1 and 4;

'R₁' represents benzyl, t-butyl or 9-fluorenylmethyl; and


'R₂' represents



wherein R₃, R₄, R₅ and R₆ each independently represent lower alkyl
or -S⁺R₇R₈, wherein R₇ and R₈ each independently represent lower alkyl
or a pharmaceutically and/or veterinarily acceptable derivative thereof.

2. (Original) A compound according to Claim 1 wherein X is an *L*-amino acid group.
3. (Currently amended) A compound according to Claim 1 ~~or 2~~ wherein X is selected from the group consisting of phenylalanine, glutamine (or an N-substituted derivative thereof), isoleucine, alanine, glycine, tyrosine, proline, serine, lysine and glutamic acid.
4. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein 'n' is 2.
5. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R₁ is benzyl.


6. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R_2 represents




7. (Currently amended) A compounds according to claim 1 ~~any one of the preceding claims~~ wherein R_2 represents $-S^+R_7R_8$, wherein R_7 and R_8 each independently represent lower alkyl.

8. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R_3 , R_4 , R_5 , R_6 , R_7 and/or R_8 are $-CH_3$ or $-CHCH_2$.

9. (Original) A compound according to Claim 1 having the following formula:



10. (Original) A compound according to Claim 1 having the following formula:




- CC(C)C(=O)NC(=O)OCC(=O)OCC(=O)SC(C)(C)[S+](C)(C)C


- CC(C(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)OCCc2ccccc2C(=O)OCC(C)S+(C)C

13. (Canceled).


14. (Original) A compound according to Claim 1 having the following formula:




15. (Original) A compound according to Claim 1 having the following formula:




16. (Original) A compound according to Claim 1 having the following formula:




17. (Original) A compound according to Claim 1 having the following formula:




18. (Original) A compound according to Claim 1 having the following formula:




19. (Original) A compound according to Claim 1 having the following formula:




20. (Original) A compound according to Claim 1 having the following formula:




21. (Original) A compound according to Claim 1 having the following formula:




22. (Original) A compound according to Claim 1 having the following formula:




23. (Original) A compound according to Claim 1 having the following formula:




24. (Original) A compound according to Claim 1 having the following formula:




25. (Original) A compound according to Claim 1 having the following formula:



26. (Original) A compound according to Claim 1 having the following formula:



27. (Original) A compound according to Claim 1 having the following formula:



28. (Currently amended) A compound according to ~~any one of Claims 1 to 27~~ claim 1 in the form of a bromide salt.

29. (Currently amended) A pharmaceutical formulation comprising a compound according to ~~any one of Claims 1 to 28~~ claim 1 and a pharmaceutically acceptable carrier.

30. (Currently amended) A method for making a compound according to ~~any one of Claims 1 to 28~~ claim 1 comprising the following steps:

(a) reacting an *N*- α -protected (~~e.g. CBZ, FMOC or BOC protected~~) amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester with 6-diazo-5-oxo-L-norleucine, and treating the resulting coupled product with hydrogen bromide; and

(b) reacting the bromomethyl ketone produced in step (a) with dimethyl sulphide, diethyl sulphide or 1,3,4,5-tetra-methyl mercapto-imidazoline-2-thione.

31. (Original) A method according to Claim 30 wherein the *N*- α -protected amino acid *N*-hydroxysuccinimide ester is CBZ, FMOC or BOC protected.

32. (Currently amended) A method according to Claim 30 ~~or 31~~ wherein step (a) comprises reacting an *N*- α -protected amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester with 6-diazo-5-oxo-L-norleucine in the presence of tetrahydrofuran (THF), water and triethylamine followed by reacting the products thereof with hydrogen bromide in the presence of ethyl acetate.

33. (Currently amended) A method according to Claim 31 ~~or 32~~ wherein the *N*- α -CBZ-protected amino acid *N*-hydroxy-succinimide ester is selected from the group consisting of *N*- α -CBZ-*L*-phenylalanine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glutamine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-isoleucine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-alaninal *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glycine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-

proline *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-serine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-tyrosine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-glutamic acid *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-lysine *N*-hydroxysuccinimide ester and *N*- α -CBZ-*L*-tyrosine *para*-nitrophenyl ester.

34-36. (Canceled).

37. (Currently amended) ~~The use according to Claim 35 or 36 wherein the medicament is for treating~~ A method for treating a patient suffering from a disease/disorder selected from the group consisting of fibrosis, scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, proliferative disorders, AIDS, psoriasis, ~~cancer, fibrosis, scarring~~ and inflammation (such as chronic inflammatory diseases), the method comprising administering a composition comprising the compound of Claim 1.

38. (Currently amended) The use according to ~~any one of Claims 35 to 37~~ wherein the medicament is for treating cancer.

39-40. (Canceled)

41. (Currently amended) ~~Use of a compound according to any one of Claims 1 to 28 in the preparation of a medicament for preventing or treating~~ A method for treating a patient to prevent or treat rejection of a transplanted organ.

42. (Currently amended) ~~A use according to~~ The method of Claim 41 wherein the organ is a heart, lung, kidney or liver.

43. (Currently amended) ~~A use according to~~ The method of Claim 41 ~~or 42~~ wherein the organ is treated prior to transplantation.

Applicant : Martin Griffin et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 14 of 15

Attorney's Docket No.: 11897-007US1/ NOTBA/P30447US

44. (Currently amended) ~~A use according to any one~~ The method of Claims 41 to 43
wherein the organ is treated during and/or after transplantation into a patient.